The Patent Finder

Cell Penetrating Peptides and Methods of Making and Using Thereof

Entrada Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/US2015/032043, filed May 21, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 11,225,506Cell Penetrating Peptides and Methods of Making and Using Thereof
In force
 · High confidence
UsedRemaining
Entrada Therapeutics, Inc.In forceHigh confidence
US 10,815,276Cell Penetrating Peptides and Methods of Making and Using Thereof
In force
 · High confidence
Entrada Therapeutics, Inc.In forceHigh confidence
US 10,626,147Cell Penetrating Peptides and Methods of Making and Using Thereof
In force
 · High confidence
Entrada Therapeutics, Inc.In forceHigh confidence
Application 17/530,664Cell Penetrating Peptides and Methods of Making and Using Thereof
Abandoned
Abandoned Jul 25, 2024
Entrada Therapeutics, Inc.AbandonedAbandoned Jul 25, 2024
Application 18/734,759Cell Penetrating Peptides and Methods of Making and Using Thereof
Pending
Not granted
Entrada Therapeutics, Inc.PendingNot granted
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Entrada Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited